Carelane has secured €2.6 million in seed funding led by Vorwerk Ventures to boost its AI-driven platform designed to enhance the efficiency and quality of clinical trials.

Information on the Target

Carelane is a pioneering company dedicated to transforming clinical studies through an AI-enhanced platform for clinical research. This innovative hub facilitates a significant reduction in both time and cost—reportedly saving up to 80 percent—while maintaining high quality throughout the clinical trial process. Carelane integrates all phases of clinical studies, from protocol creation to data analysis, utilizing advanced AI technology coupled with a structured digital protocol based on FHIR standards. Over 130 research sites across six continents have already adopted Carelane's software solution.

CEO Yannick Boerner emphasizes that the platform is designed to meet the intricate demands of modern clinical studies by streamlining workflows, accelerating trial execution, and enhancing overall quality. Carelane provides an all-encompassing solution that alleviates burdens on research sites by minimizing manual processes, ultimately resulting in a more efficient operation.

Industry Overview in Germany

The clinical research industry in Germany is increasingly complex, characterized by a growing demand for efficient and high-quality studies. As one of Europe's leading nations in clinical trials, Germany boasts a robust ecosystem of research